BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, May 17, 2026
Home » Blogs » BioWorld MedTech Perspectives » Three from MDD; Star Trek, big business, and human foibles

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Three from MDD; Star Trek, big business, and human foibles

May 2, 2013
By Mark McCarty

Starship enterprise
Medical science boldly going

 

The pages of Medical Device Daily are chock-full of outstanding content, but here are three stories from the month of April that caught my eye.

Taking the eye out of ouch

Seventh Sense Biosystems announced a registration trial for its TAP (touch-activated phlebotomy) device, which is one of those things that in times gone by was strictly the stuff of science fiction television shows. As my colleague Amanda Pedersen wrote in the April 3 edition, the TAP makes use of microneedles to obtain blood from the capillaries, and can dispense a small dose of anti-coagulant to keep things moving if need be.

This is real Star Trek stuff if you ask me. The company’s CEO, Howard Weisman, perhaps understated the case when he told Amanda the device got around “the pain and anxiety” of routine blood draws “because you don’t see the needle.”

I don’t see myself as particularly squeamish, but I don’t look at needles at all. I turn my head if I need a shot. In my view, you have to be a little crazy if you actually watch it all happen.

Three cheers for Seventh Sense, but tell me again who got sixth?

Consolidation in diagnostic services

Thermo Fisher and Life Technologies shook hands over a deal that would give the latter’s shareholders about $76 a share in a consolidation in the life science services industry. Both companies offer diagnostic lab services, and the terms of the deal make it a purchase coming to close to $14 billion plus any remaining debt on Life Technologies’ books, which may run to about $2 billion.

As Omar Ford wrote in the April 16 edition of Medical Device Daily, Thermo Fisher needed some help from a couple of investment banks to pull it off, which indicates the firm’s board of directors saw this as either too good to pass up or vital to the company’s future … or both. In any case, the deal probably won’t close until early next year.

Will a bidding war for Life Sciences ensue?

Collegiality at hospitals an issue?

Medical errors are still a topic among physicians and policymakers, and former Medical Device Daily executive editor Jim Stommen authored a two-part interview with Frederick Southwick, MD, of the University of South Florida about this.

Southwick told Jim – who I might note is something of a legend among the editorial staff at MDD’s publisher, AHC Media – that one of the impediments to efforts to tamp down on iatrogenic disease and injury is a cultural one. Southwick said hierarchies are of sufficient stiffness in many hospitals that “there is not a sense of collegiality that’s needed in order to foster teamwork.” He also remarked that hospital staff “tend to be disorganized in the way we communicate.”

Don’t get me wrong, I love technology as much as the next policy wonk, but if Southwick is right on the hierarchy point, it’s another demonstration of the need for we humans to get out of our own darn way. This is something technology cannot fix.

I’m not saying I never have such issues, and I’m also not saying I’d trade places with a doctor. People in all lines of work tend to lead with their egos, but when running unchecked in a hospital, this very understandable human impulse can cost lives.

But who, besides Southwick, is talking about it?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 15, 2026.
  • Illustration of a glowing circle to represent circRNA

    ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

    BioWorld
    Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • 3D illustration of adeno-associated viruses

    ASGCT 2026: Uncovering the mechanisms of AAV toxicity

    BioWorld
    Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
  • Amyloid plaques on nerve cell

    Roche secures CE mark for Alzheimer’s blood test

    BioWorld
    Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing